Under 10% of people that would benefit from weight-loss injections such as Wegovy have access to them, states the World Health Organization as it issues its inaugural recommendations on the therapies.
Given in excess of 1,000,000,000 individuals worldwide now living with obesity, it is calling for increased and just access to GLP-1 medication.
Based on projections, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"Our new guidance affirms that excess weight is a lifelong illness that can be addressed with thorough and lifelong treatment," said its chief Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are significant obstacles to widespread access to the jabs that can assist patients in reducing substantial weight, notes the organization.
Skinny Jab Shortage
Despite the current most optimistic case, the supply of these medications might only reach approximately 100 million people – less than 10% of those who need them, per the health organization.
The guideline encourages countries and companies to increase availability, by approaches including licensing agreements.
The intellectual property rights on a key compound – the main component of a leading brand – is set to lapse in a number of countries in 2026.
How Obesity Jabs Function
The injections mimick a natural hormone to slow digestion, suppress the appetite and enhance satiety so people consume fewer calories.
People commonly see weight reduction after several weeks of commencing the once-weekly jabs.
Studies indicates people may regain a significant portion after a year of stopping the medication, as their typical hunger resume.
To be carrying excess weight elevates your risk for contracting medical conditions, such as type 2 diabetes, cardiovascular issues, stroke, and some cancers.
Excess weight impacts people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, per the health agency.
